PMID- 37254146
OWN - NLM
STAT- MEDLINE
DCOM- 20230601
LR  - 20230602
IS  - 1470-7330 (Electronic)
IS  - 1740-5025 (Print)
IS  - 1470-7330 (Linking)
VI  - 23
IP  - 1
DP  - 2023 May 30
TI  - Comparing the effectiveness and safety of Sorafenib plus TACE with Apatinib plus 
      TACE for treating patients with unresectable hepatocellular carcinoma: a 
      multicentre propensity score matching study.
PG  - 52
LID - 10.1186/s40644-023-00574-7 [doi]
LID - 52
AB  - OBJECTIVE: Local combined systemic therapy has been an important method for the 
      treatment of unresectable hepatocellular carcinoma (HCC).The purpose of this 
      study was to compare the effectiveness and safety of transarterial 
      chemoembolization (TACE) plus Sorafenib versus TACE plus Apatinib for treating 
      patients with unresectable HCC. METHODS: The clinical data of patients with 
      unresectable HCC who were treated with TACE plus Sorafenib or TACE plus Apatinib 
      at 5 Chinese medical centers between January 2016 and December 2020 were 
      retrospectively analyzed. Propensity score matching (PSM) was applied to reduce 
      the bias from confounding factors. RESULTS: A total of 380 patients were 
      enrolled, of whom 129 cases were treated with TACE plus Sorafenib and 251 cases 
      with TACE plus Apatinib. After the 1:1 PSM, 116 pairs of patients were involved 
      in this study. The results showed that the PFS and OS in the TACE-Sorafenib group 
      were significantly longer than those in the TACE-Apatinib group (PFS: 
      16.79 +/- 6.45 vs. 14.76 +/- 6.98 months, P = 0.049; OS: 20.66 +/- 6.98 vs. 
      17.69 +/- 6.72 months, P = 0.013). However, the ORR in the TACE-Apatinib group was 
      markedly higher than that in the TACE-Sorafenib group (70.69% vs. 56.03%, 
      P = 0.021). There were more patients with adverse events (AEs) in the 
      TACE-Apatinib group than those in the TACE-Sorafenib group before dose adjustment 
      (87 vs. 63, P = 0.001); however, the number of patients who suffered from AEs was 
      not significantly different between the two groups after the dose adjustment (62 
      vs. 55, P = 0.148). No treatment-related death was found in the two groups. 
      Subgroup analysis revealed that patients with unresectable HCC could better 
      benefit from regular doses than reduced doses (Sorafenib, 22.59 vs. 18.02, 
      P < 0.001; Apatinib, 19.75 vs. 16.86, P = 0.005). CONCLUSION: TACE plus either 
      Sorafenib or Apatinib could effectively treat patients with unresectable HCC, the 
      safety of TACE plus Sorafenib was better. and the ORR of TACE plus Apatinib was 
      higher.
CI  - (c) 2023. The Author(s).
FAU - Yin, Liang
AU  - Yin L
AD  - Department of Interventional Radiology, The First Affiliated Hospital of USTC, 
      Division of Life Sciences and Medicine, University of Science and Technology of 
      China, Hefei, 230001, Anhui, China.
FAU - Liu, Kai-Cai
AU  - Liu KC
AD  - Infection Hospital, The First Affiliated Hospital of USTC, Division of Life 
      Sciences and Medicine, University of Science and Technology of China, Hefei, 
      230000, Anhui, China.
FAU - Lv, Wei-Fu
AU  - Lv WF
AD  - Department of Interventional Radiology, The First Affiliated Hospital of USTC, 
      Division of Life Sciences and Medicine, University of Science and Technology of 
      China, Hefei, 230001, Anhui, China. weifulv@ustc.edu.cn.
FAU - Lu, Dong
AU  - Lu D
AD  - Department of Interventional Radiology, The First Affiliated Hospital of USTC, 
      Division of Life Sciences and Medicine, University of Science and Technology of 
      China, Hefei, 230001, Anhui, China.
FAU - Tan, Yu-Lin
AU  - Tan YL
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Bengbu 
      Medical University, Bengbu, 233004, Anhui, China.
FAU - Wang, Guo-Xiang
AU  - Wang GX
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Wannan 
      Medical College, Wuhu, 241002, Anhui, China.
FAU - Dai, Jia-Ying
AU  - Dai JY
AD  - Department of Interventional Radiology, Anqing Municipal Hospital, Anqing, 
      246003, Anhui, China.
FAU - Zhu, Xian-Hai
AU  - Zhu XH
AD  - Department of Interventional Radiology, The First Affiliated Hospital of USTC, 
      Division of Life Sciences and Medicine, University of Science and Technology of 
      China, Hefei, 230001, Anhui, China.
FAU - Jiang, Bo
AU  - Jiang B
AD  - Department of Interventional Ultrasound, The Second Affiliated Hospital of Anhui 
      Medical University, Hefei, 230000, China.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20230530
PL  - England
TA  - Cancer Imaging
JT  - Cancer imaging : the official publication of the International Cancer Imaging 
      Society
JID - 101172931
RN  - 9ZOQ3TZI87 (Sorafenib)
RN  - 5S371K6132 (apatinib)
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Hepatocellular/drug therapy/pathology
MH  - Sorafenib/therapeutic use
MH  - *Liver Neoplasms/drug therapy/pathology
MH  - *Antineoplastic Agents/therapeutic use
MH  - Propensity Score
MH  - Retrospective Studies
MH  - *Chemoembolization, Therapeutic/methods
MH  - Combined Modality Therapy
PMC - PMC10230673
OTO - NOTNLM
OT  - Apatinib
OT  - Clinical outcomes
OT  - Hepatocellular carcinoma
OT  - Sorafenib
OT  - Transarterial chemoembolization
COIS- Nil.
EDAT- 2023/05/31 01:09
MHDA- 2023/06/01 06:42
PMCR- 2023/05/30
CRDT- 2023/05/30 23:39
PHST- 2022/07/20 00:00 [received]
PHST- 2023/05/22 00:00 [accepted]
PHST- 2023/06/01 06:42 [medline]
PHST- 2023/05/31 01:09 [pubmed]
PHST- 2023/05/30 23:39 [entrez]
PHST- 2023/05/30 00:00 [pmc-release]
AID - 10.1186/s40644-023-00574-7 [pii]
AID - 574 [pii]
AID - 10.1186/s40644-023-00574-7 [doi]
PST - epublish
SO  - Cancer Imaging. 2023 May 30;23(1):52. doi: 10.1186/s40644-023-00574-7.